Adding tafasitamab to treatment with lenalidomide and rituximab improved progression-free survival in patients with relapsed or refractory follicular lymphoma.

With a median follow-up of 14.1 months, adding tafasitamab to lenalidomide and rituximab reduced the risk of progression, ...

Treatment with tafasitamab for relapsed/refractory DLBCL in the United States was supported by data from a retrospective analysis.

Adding the humanized CD19-targeted monoclonal antibody tafasitamab (Monjuvi) to a backbone of lenalidomide (Revlimid) and ...

Incyte (INCY) announced additional results from the pivotal Phase 3 inMIND trial evaluating treatment with tafasitamab, a humanized Fc-modified ...

Elizabeth A. Brem, MD, an assistant clinical professor in the Division of Hematology/Oncology, School of Medicine at the University of California, Irvine, discusses multiple types of therapies used in ...

The inMIND trial results have elevated expectations for Monjuvi's commercial success, but competition is on the horizon.

The global Minimal Residual Disease market is expected to grow to USD 2.55 Billion by 2029, up from USD 1.43 Billion in 2024, ...

Ounce of Hope, a leading aquaponic cannabis brand, is redefining industry standards by pairing sustainable, aquaponic ...

BMO Capital analyst Evan Seigerman maintained a Sell rating on Incyte (INCY – Research Report) yesterday and set a price target of $52.00.Pick ...

Tafasitamab binds to CD19, a protein on the surface of B-cells that is also targeted by three CAR-T therapies – Novartis' Kymriah (tisagenlecleucel), Gilead's Yescarta (axicabtagene ciloleucel ...